Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS inactivates RB1 via CDK4/6, while RB1 mutation is rare. Thus, CDK4/6 ...

SAN ANTONIO — For patients with advanced hormone receptor-positive, HER2-negative breast cancer, health-related quality of life is the same whether they receive CDK4/6 inhibitors in the first or ...

With an estimated 1.5 million new cases and 397,000 deaths worldwide, prostate cancer is the world's second most frequent cancer and the fifth leading cause of cancer death among men in 2022. Hormone ...

Targeted cancer drugs known as CDK4/6 inhibitors have improved outcomes for patients with advanced or metastatic HR+/HER2- breast cancer, but many patients still eventually relapse and become ...

In the decade since palbociclib (Ibrance) received FDA approval, results from multiple clinical trials have provided a strong evidence base to make cyclin-dependent kinase (CDK)4/6 inhibitors, in ...

A leading breast cancer specialist examines the growing role of CDK4/6 inhibitors in the adjuvant treatment of HR+/HER2- early breast cancer, citing the monarchE and NATALEE trials, and explores ...

The combination of CDK4/6 inhibitors with endocrine therapy for estrogen receptor (ER)-positive, human epidermal growth factor 2 (HER2)-negative metastatic breast cancer (MBC) continues to be among ...

On November 27, Nature published the results of an innovative breast cancer research project from the Netherlands. This study, the SONIA trial, showed that delaying and shortening the duration of a ...

A panel of experts discuss the variables of dosage and patient adherence in regards to managing toxicities from CDK4/6 inhibitors. Dr. O’Shaughnessy discusses how she weighs clinical benefits against ...

A machine learning (ML) model incorporating both clinical and genomic factors outperformed models based solely on either clinical or genomic data in predicting which patients with hormone receptor (HR ...